Back to top
more

Karyopharm Therapeutics (KPTI)

(Delayed Data from NSDQ)

$0.88 USD

0.88
854,930

-0.01 (-0.61%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $0.87 -0.01 (-0.78%) 5:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Drugs

Zacks News

Do Options Traders Know Something About Karyopharm (KPTI) Stock We Don't?

Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.

What's in Store for AstraZeneca (AZN) This Earnings Season?

AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.

What's in Store for Acorda (ACOR) This Earnings Season?

During Acorda's (ACOR) Q4 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug Inbrija.

What's in Store for Ironwood (IRWD) This Earnings Season?

Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.

Options Traders Expect Huge Moves in Karyopharm (KPTI) Stock

Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.

BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU

The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.

Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I

Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.

Top Ranked Momentum Stocks to Buy for January 13th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 13th

Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics

Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics

Nalak Das headshot

5 Stocks With Recent Price Strength for Spectacular Returns

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Are You Looking for a Top Momentum Pick? Why Karyopharm Therapeutics (KPTI) is a Great Choice

Does Karyopharm Therapeutics (KPTI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4%

Karyopharm (KPTI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 20.24% and 718.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Signs $150M Royalty Agreement to Support Xpovio

Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.

Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study

Bristol-Myers (BMY) announces dismal results from a late-stage study on its immuno-oncology drug Opdivo for critical brain tumor.

Earnings Preview: Karyopharm Therapeutics (KPTI) Q2 Earnings Expected to Decline

Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Karyopharm Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Karyopharm Therapeutics.

Karyopharm Gets Accelerated FDA Approval for Myeloma Drug

Karyopharm (KPTI) gets accelerated FDA approval for oral Xpovio in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.

Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options

Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Misses Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -29.76% and -79.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Karyopharm Therapeutics (KPTI) Q1 Earnings Expected to Decline

Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict

Karyopharm's (KPTI) stock rises despite the FDA's decision to delay the verdict on the NDA filing of selinexor, which is developed for treating patients with relapsed-refractory multiple myeloma.

Karyopharm Files MAA for Myeloma Candidate Selinexor in EU

Karyopharm (KPTI) tenders a marketing application to European regulatory authority with the purpose of seeking an approval for selinexor to address patients with penta-refractory multiple myeloma.

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 10.23% and -80.25%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 21.05% and 233.07%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?